Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Int J Cancer. 2021 Dec 1;149(11):1955-1960. doi: 10.1002/ijc.33749. Epub 2021 Aug 4.
The value of high-throughput germline genetic testing is increasingly recognized in clinical cancer care. Disease-associated germline variants in cancer patients are important for risk management and surveillance, surgical decisions and can also have major implications for treatment strategies since many are in DNA repair genes. With the increasing availability of high-throughput DNA sequencing in cancer clinics and research, there is thus a need to provide clinically oriented sequencing reports for germline variants and their potential therapeutic relevance on a per-patient basis. To meet this need, we have developed the Cancer Predisposition Sequencing Reporter (CPSR), an open-source computational workflow that generates a structured report of germline variants identified in known cancer predisposition genes, highlighting markers of therapeutic, prognostic and diagnostic relevance. A fully automated variant classification procedure based on more than 30 refined American College of Medical Genetics and Genomics (ACMG) criteria represents an integral part of the workflow. Importantly, the set of cancer predisposition genes profiled in the report can be flexibly chosen from more than 40 virtual gene panels established by scientific experts, enabling customization of the report for different screening purposes and clinical contexts. The report can be configured to also list actionable secondary variant findings, as recommended by ACMG. CPSR demonstrates comparable sensitivity and specificity for the detection of pathogenic variants when compared to other algorithms in the field. Technically, the tool is implemented in Python/R, and is freely available through Docker technology. Source code, documentation, example reports and installation instructions are accessible via the project GitHub page: https://github.com/sigven/cpsr.
高通量种系基因检测在临床癌症治疗中的价值正日益得到认可。癌症患者的种系疾病相关变异对风险管理和监测、手术决策很重要,并且由于许多与 DNA 修复基因有关,因此对治疗策略也有重大影响。随着高通量 DNA 测序在癌症临床和研究中的日益普及,因此需要根据每个患者的情况,提供针对种系变异及其潜在治疗相关性的具有临床导向的测序报告。为了满足这一需求,我们开发了癌症易感性测序报告(Cancer Predisposition Sequencing Reporter,CPSR),这是一个开源的计算工作流程,可生成在已知癌症易感性基因中识别出的种系变异的结构化报告,突出显示具有治疗、预后和诊断相关性的标志物。基于 30 多项经过精炼的美国医学遗传学与基因组学学会(American College of Medical Genetics and Genomics,ACMG)标准的全自动变异分类程序是该工作流程的一个组成部分。重要的是,报告中分析的癌症易感性基因集可以从由科学专家建立的 40 多个虚拟基因面板中灵活选择,从而能够根据不同的筛查目的和临床环境定制报告。该报告还可以配置为列出 ACMG 推荐的可操作的次要变异发现。CPSR 在检测致病性变异方面的灵敏度和特异性与该领域的其他算法相当。从技术上讲,该工具是用 Python/R 实现的,并且可以通过 Docker 技术免费获得。源代码、文档、示例报告和安装说明可通过项目的 GitHub 页面访问:https://github.com/sigven/cpsr。